Clinical trials: Digestive Neoplasms
Hepatocellular Carcinoma
Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation
This study is a randomized, open-label, controlled study that will explore the efficacy of individualized adjuvant chemotherapy based on the adenosine triphosphate tumor chemosensitivity assay for patients with hepatocellular…
- Trial name
- NCT02580253
- Testing
- Individualized Chemotherapy, mFOLFOX6
- Where
- China
- Sponsor
- Zhejiang University
Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has…
- Conditions
- Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- PRIMIER (NCT02413853)
- Testing
- CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium
- Where
- United States
- Sponsor
- University of Southern California
Esophageal Cancer
Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
- Trial name
- NCT03120572
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Mackay Memorial Hospital
Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the outcomes and identify predictors of neoadjuvant anti-PD-1 plus chemotherapy in locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT05740995
- Testing
- neoadjuvant anti-PD-1 plus chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Solid Tumors
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor…
- Trial name
- NCT01938612
- Testing
- MEDI4736, tremelimumab
- Where
- 21 sites in Japan, South Korea and 1 more
- Volunteers
- 269 people
- Sponsor
- AstraZeneca
Malignant Solid Tumour, Breast Cancer
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an…
- Conditions
- Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST
- Trial name
- NCT01376505
- Testing
- HER-2 vaccine, Extension HER-2 vaccine trial at OBD
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Robert Wesolowski
Colorectal Cancer
Acute PresentatiOn of CoLorectaL Cancer: an internatiOnal Snapshot
APOLLO (Acute PresentatiOn of CoLorectaL Cancer: an internatiOnal snapshot) is an international, multi-centre, prospective observational study which will address this need and aims to describe the operative and non-operative…
- Trial name
- APOLLO (NCT05641129)
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- European Student Research Network
Anal Cancer, Colorectal Cancer
Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients
Primary Objectives: To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (interleukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha [TNF] and symptoms related to…
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00502502
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Rectal Cancer
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal…
- Trial name
- NCT06304545
- Testing
- Camrelizumab, Chemotherapy, Radiotherapy
- Volunteers
- 48 people
- Sponsor
- Harbin Medical University
Esophageal Neoplasms, Esophagectomy
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be…
- Conditions
- Esophageal Neoplasms, Esophagectomy, Brain Metastases
- Trial name
- METABREC (NCT04654975)
- Testing
- Esophagectomy for esophageal cancer
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 10,000 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pancreatic Cancer, Advanced Cancer
LY3214996 +/- HCQ in Pancreatic Cancer
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
- Trial name
- NCT04386057
- Testing
- Hydroxychloroquine Sulfate, LY3214996
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kimberly Perez, MD
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Gastrointestinal Stromal Tumors
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
This is a prospective, multicenter, observational real-world study to explore the second-line Pharmacotherapy patterns and clinical outcomes in GIST patients who progressed on or were intolerant to first-line anticancer treatment.
- Trial name
- NCT05440357
- Where
- 8 sites in China
- Volunteers
- 100 people
- Sponsor
- Xinhua Zhang, MD
Colorectal Cancer
WT1 in Colorectal Adenocarcinoma
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors.
- Trial name
- NCT07778628
- Testing
- immunohistochemical staining with WT1 antibody
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Colon Cancer
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).
- Trial name
- RESET-C (NCT05662527)
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Camilla Qvortrup
Hepatocellular Carcinoma, Cirrhosis
Estimation of Functional Liver Reserve Using Cholinesterases
Estimation of functional liver reserve in patients with hepatocellular carcinoma (HCC) in cirrhosis is of paramount importance to properly select candidates for surgical resection.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver Neoplasm, Liver Disease
- Trial name
- NCT00883454
- Where
- Italy
- Volunteers
- 181 people
- Sponsor
- University of Milan
Hepatocellular Carcinoma
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
The hope to treat more patients with hepatocellular carcinoma successfully is however tempered by the shortage of donors leading to an increasing waiting time for liver transplantation (LT).
- Trial name
- CATCH (NCT01676194)
- Testing
- Intra-arterial administration of DC BeadsR
- Where
- 7 sites in France
- Volunteers
- 7 people
- Sponsor
- Rennes University Hospital
Stomach Cancer, Stomach Neoplasm
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
The primary objective is to evaluate six months survival rate and quality of life at 4 months of ramucirumab alone or in combination with paclitaxel in patients aged 70 years or more who have stomach or GEJ adenocarcinoma and…
- Conditions
- Stomach Cancer, Stomach Neoplasm, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- SOCRATE (NCT03760822)
- Testing
- Ramucirumab, Paclitaxel
- Where
- 38 sites in France
- Volunteers
- 112 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Colon Cancer, PCSK9 Inhibitor
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Conditions
- Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
- Trial name
- TRIUNITE-08 (NCT07840677)
- Testing
- Tafolecimab, Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.